An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis (IMAGINE-RA)
Does an MRI-guided Treatment Strategy Reduce Disease Activity and Progression in Patients With Rheumatoid Arthritis (RA): a Randomised Controlled Trial
研究概览
地位
详细说明
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. Patients typically experience pain, functional impairment and reduced quality of life, and are at risk of developing progressive joint damage. The disease primarily affects the small joints of the hands and feet. The current treatment strategy involves early and intensive treatment with close clinical follow up, which attempts to control the disease and avoid inflammation and thereby prevent pain, improve functional level and avoid joint damage. It is therefore important for optimal treatment of RA patients that methods used for diagnosis, disease monitoring and prognostication are highly sensitive. Erosive joint damage occurs early in the disease. Joint deformity is irreversible and causes serious functional impairment. Early and intensive treatment with close monitoring of the inflammation can slow the destructive disease and prevent function loss. However, it has been demonstrated that patients who are shown by conventional clinical and biochemical examination to have low disease activity or to be in remission can still have progressive joint damage. This demonstrates that current clinical/biochemical methods used in daily clinical practice are not sufficiently sensitive and other methods are required for the monitoring of disease activity and prognostication.
The presence of erosions (shown by X-ray examination) as well as anti-cyclic citrullinated peptide (anti-CCP) antibodies and bone marrow oedema (osteitis) on magnetic resonance imaging (MRI), are all independent predictors of subsequent radiographic progression. Bone marrow oedema has been shown to be the strongest independent predictor in early RA and MRI therefore has significant prognostic value.
It is therefore possible that supplementing conventional clinical and biochemical examinations of RA patients with MRI, and intensifying treatment where bone marrow oedema is present, will help reduce disease activity, avoid progressive joint damage and prevent function loss.
The current study is therefore based on the following hypothesis:
By supplementing conventional clinical and biochemical examination of RA patients with low disease activity/in remission with MRI and intensifying treatment in the case of sub-clinical inflammation as measured by the presence of bone marrow oedema, it is possible to prevent radiographic erosive progression, improve functional level and enable more patients to achieve clinical remission.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Aarhus、丹麦、8600
- Dep. of Rheumatology Aarhus Hospital
-
Copenhagen、丹麦、2000
- Dep. of Rheumatology Frederiksberg Hospital
-
Copenhagen、丹麦、2600
- Dep. of Rheumatology Glostrup Hospital
-
Copenhagen、丹麦、2900
- Dep. of Rheumatology Gentofte Hospital
-
Graasten、丹麦、6300
- Dep. of Rheumatology King Christian X´Hospital for Rheumatic Diseases
-
Hjørring、丹麦、DK-9800
- Department of Rheumatology University Hospital Vendsyssel
-
Odense、丹麦、5000
- Dep. of rheumatology Odense Hospital
-
Silkeborg、丹麦、8600
- Dep. of Rheumatology Silkeborg Hospital
-
Slagelse、丹麦、4200
- Dep. of Rheumatology Slagelse Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age > 18 years
- RA according to ACR (American College of Rheumatology)/EULAR (European League Against Rheumatism) 2010 criteria.
- Anti-CCP positivity
- Erosions on conventional X-ray of hands, wrists and/or feet
- No clinically swollen joints
- DAS28 (4 variable, CRP) < 3.2
- DMARD monotherapy treatment OR combination treatment, in the form of 2- or 3-drug therapy. If the patient is undergoing 3-drug therapy, at least one of the preparations must be administered at less than the "maximum inclusion dose"*
- Unchanged anti-rheumatic treatment in the previous 6 weeks or more
- No previous treatment with biological medication
- No contra-indications for TNF-alpha-inhibiting treatment
- No contra-indications for MRI
- s-creatinine within normal range
Ability and willingness to give written and oral informed consent and fulfil the requirements of the study programme with reference to the protocol
- Maximum "inclusion dose" is defined as: MTX 25 mg/week (or maximum tolerated dose if 25 mg/week is not tolerated), SSZ 2g/day (or maximum tolerated dose if 2 g/day is not tolerated) and HCQ 200 mg/day (or maximum tolerated dose if 200 mg/day is not tolerated)
Exclusion Criteria:
- Previous or current biological treatment
- Known intolerance to methotrexate treatment which means that the patient is not able to tolerate a minimum of MTX 7.5 mg (minimum dose).
- DMARD 3-drug therapy at maximum tolerated/maximum "inclusion dose"*
- I.m, intra-articular or i.v glucocorticoid administration ≤ 6 weeks prior to inclusion
- Oral glucocorticoid administration > 5 mg/day
- Changes in oral glucocorticoid dose < 3 months prior to inclusion
- Myocrisin treatment
- Affected liver enzymes > 2 x the upper limit of normal at the time of screening
- Current and/or imminent wish to become pregnant
- Contra-indications for TNF-alpha-inhibiting treatment
- Contra-indications for MRI
- Known alcohol/drug abuse
- Inability to give informed consent
- Inability to cooperate with the study programme due to physical or mental reasons
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器：Conventional biochemical and clinical examinations
Biochemical and clinical examinations
|
Treatment algorithm based on conventional biochemical and clinical examinations.
Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of "unsatisfactory inflammatory activity", which is defined as the presence of at least one clinically swollen joint and DAS28>3.2
|
|
实验性的：Conventional biochemical and clinical examinations and MRI.
Biochemical and clinical examinations and MRI.
|
Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side.
Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of "unsatisfactory inflammatory activity", which is defined as the presence of at least one physically swollen joint and DAS28>3.2
AND/OR MRI-detected bone marrow oedema score > 0 (RAMRIS-score)
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
DAS28 remission (<2.6)
大体时间：24 month
|
24 month
|
|
No radiographic progression (assessed by the Sharp/vdHeijde method).
大体时间：24 month
|
24 month
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
No radiographic progression (Sharp/vdHeijde score).
大体时间：24 month
|
No radiographic progression (Sharp/vdHeijde score) from 0-12 and 12-24 months and change in Sharp/vdHeijde score from 0-12, 0-24 and 12-24 months.
|
24 month
|
|
No MRI erosion (RAMRIS) score
大体时间：24 month
|
No progression in MRI erosion (RAMRIS) score from 0-12 and 12-24 months and change in MRI erosion (RAMRIS) score from 0-12, 0-24 and 12-24 months.
|
24 month
|
|
MRI synovitis (RAMRIS) score
大体时间：24 months
|
MRI synovitis (RAMRIS) score at 12 and 24 months
|
24 months
|
|
MRI bone marrow oedema (RAMRIS) score
大体时间：24 months
|
MRI bone marrow oedema (RAMRIS) score at 12 and 24 months
|
24 months
|
|
HAQ score
大体时间：24 month
|
Changes in HAQ score from 0-12 and 0-24 months
|
24 month
|
|
SF-36 score
大体时间：24 month
|
Changes in SF-36 score from 0-12 and 0-24 months
|
24 month
|
|
EQ-5D score
大体时间：24 month
|
Changes in EQ-5D score from 0-12 and 0-24 months
|
24 month
|
|
ACR/EULAR 2011 remission
大体时间：24 month
|
ACR/EULAR 2011 remission at 12 and 24 months
|
24 month
|
|
DAS28
大体时间：24 month
|
DAS28 at 12 and 24 month
|
24 month
|
|
DAS28 remission (<2.6) at 12 months
大体时间：24 months
|
24 months
|
|
|
biomarker analyses
大体时间：24 month
|
24 month
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dynamic MRI
大体时间：24 month
|
Dynamic MRI variable (including initial rate of enhancement (IRE) and maximum enhancement (ME)).
|
24 month
|
合作者和调查者
合作者
调查人员
- 首席研究员：Kim Hørslev-Petersen, Professor、King Christian X´Hospital for Rheumatic Diseases
- 研究主任：Signe Møller-Bisgaard, MD、Dep. of Rheumatology, Rigshospitalet, Glostrup
- 学习椅：Mikkel Østergaard, Professor、Dep. of Rheumatology, Rigshospitalet, Glostrup
- 学习椅：Bo Ejbjerg, MD, PhD、Dep. of Rheumatology Slagelse Hospital
- 学习椅：Merete Hetland, MD, PhD, DMSci、Dep. of Rheumatology, Rigshospitalet, Glostrup
出版物和有用的链接
一般刊物
- Moller-Bisgaard S, Horslev-Petersen K, Ejbjerg B, Hetland ML, Christensen R, Ornbjerg LM, Glinatsi D, Moller JM, Boesen M, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Larsen L, Jurik AG, Thomsen HS, Ostergaard M. Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial. Scand J Rheumatol. 2022 Jul;51(4):268-278. doi: 10.1080/03009742.2021.1935312. Epub 2021 Sep 2.
- Moller-Bisgaard S, Georgiadis S, Horslev-Petersen K, Ejbjerg B, Hetland ML, Ornbjerg LM, Glinatsi D, Moller J, Boesen M, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Balding L, Jurik AG, Thomsen HS, Ostergaard M. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology (Oxford). 2021 Jan 5;60(1):380-391. doi: 10.1093/rheumatology/keaa496.
- Moller-Bisgaard S, Horslev-Petersen K, Ejbjerg B, Hetland ML, Ornbjerg LM, Glinatsi D, Moller J, Boesen M, Christensen R, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Nielsen SM, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Balding L, Jurik AG, Thomsen HS, Ostergaard M. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial. JAMA. 2019 Feb 5;321(5):461-472. doi: 10.1001/jama.2018.21362.
- Moller-Bisgaard S, Horslev-Petersen K, Ejbjerg BJ, Boesen M, Hetland ML, Christensen R, Moller J, Krogh NS, Stengaard-Pedersen K, Ostergaard M. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial. Trials. 2015 Apr 21;16:178. doi: 10.1186/s13063-015-0693-2.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.